Rankings
▼
Calendar
TNGX Q2 2020 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
TNGX
Tango Therapeutics, Inc.
$2B
Q2 2020 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$5M
Gross Profit
-$6M
-119.8% margin
Operating Income
-$8M
-166.7% margin
Net Income
-$8M
-165.7% margin
EPS (Diluted)
$-0.75
QoQ Revenue Growth
+7.5%
Cash Flow
Operating Cash Flow
-$11M
Free Cash Flow
-$11M
Stock-Based Comp.
$407,000
Balance Sheet
Total Assets
$63,492
Total Liabilities
$38,965
Stockholders' Equity
$24,528
Cash & Equivalents
$24,993
← FY 2020
All Quarters
Q3 2020 →